The following company announcements are just a few of the specialty pharmacy company activities from this month. Subscribe to AMI’s Specialty Pharmacy Database to stay up to date on company and industry trends
WAINUA™ for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis is available at Orsini Specialty Pharmacy
Investment positions Orsini Specialty Pharmacy for continued expansion of patient access and support services across therapies for highly complex and rare diseases
Alnylam® Pharmaceuticals selected PantherRx Rare and Orsini Specialty Pharmacy as limited distribution partners for OXLUMO™ (lumasiran). OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that […]
The number of chronic infusion therapies for neuromuscular disorders continues to grow